Avadel Pharmaceuticals plc (NASDAQ: AVDL) started the day on Wednesday, with a price decrease of -3.36% at $13.22, before settling in for the price of $13.68 at the close. Taking a more long-term approach, AVDL posted a 52-week range of $9.50-$19.09.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -40.99%. Meanwhile, its Annual Earning per share during the time was 4.78%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 74.19%. This publicly-traded company’s shares outstanding now amounts to $96.27 million, simultaneously with a float of $90.35 million. The organization now has a market capitalization sitting at $1.27 billion.
Avadel Pharmaceuticals plc (AVDL) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Drug Manufacturers – Specialty & Generic Industry. Avadel Pharmaceuticals plc’s current insider ownership accounts for 6.15%, in contrast to 71.46% institutional ownership. According to the most recent insider trade that took place on Jan 16 ’24, this organization’s Chief Financial Officer bought 2,000 shares at the rate of 14.50, making the entire transaction reach 29,000 in total value, affecting insider ownership by 80,500. Preceding that transaction, on Dec 28 ’23, Company’s Director sold 75,000 for 14.53, making the whole transaction’s value amount to 1,089,750. This particular insider is now the holder of 67,025 in total.
Avadel Pharmaceuticals plc (AVDL) Earnings and Revenue Records
Avadel Pharmaceuticals plc’s EPS increase for this current 12-month fiscal period is 74.19% and is forecasted to reach 0.61 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 15.00% through the next 5 years, which can be compared against the 4.78% growth it accomplished over the previous five years trading on the market.
Avadel Pharmaceuticals plc (NASDAQ: AVDL) Trading Performance Indicators
Let’s observe the current performance indicators for Avadel Pharmaceuticals plc (AVDL). It’s Quick Ratio in the last reported quarter now stands at 2.52. The Stock has managed to achieve an average true range (ATR) of 0.53. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 13.38.
In the same vein, AVDL’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.15, a figure that is expected to reach -0.08 in the next quarter, and analysts are predicting that it will be 0.61 at the market close of one year from today.
